- Home
- KYN vs AGIO Comparison
KYN vs AGIO Comparison
Compare KYN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYN
- AGIO
- Stock Information
- Founded
- KYN 2004
- AGIO 2007
- Country
- KYN United States
- AGIO United States
- Employees
- KYN N/A
- AGIO N/A
- Industry
- KYN Finance/Investors Services
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- KYN Finance
- AGIO Health Care
- Exchange
- KYN Nasdaq
- AGIO Nasdaq
- Market Cap
- KYN 2.1B
- AGIO 2.4B
- IPO Year
- KYN N/A
- AGIO 2013
- Fundamental
- Price
- KYN $12.13
- AGIO $35.42
- Analyst Decision
- KYN
- AGIO Buy
- Analyst Count
- KYN 0
- AGIO 7
- Target Price
- KYN N/A
- AGIO $56.33
- AVG Volume (30 Days)
- KYN 561.5K
- AGIO 1.1M
- Earning Date
- KYN 01-01-0001
- AGIO 02-13-2025
- Dividend Yield
- KYN 8.99%
- AGIO N/A
- EPS Growth
- KYN N/A
- AGIO N/A
- EPS
- KYN 0.71
- AGIO 11.80
- Revenue
- KYN N/A
- AGIO $32,871,000.00
- Revenue This Year
- KYN N/A
- AGIO $33.38
- Revenue Next Year
- KYN N/A
- AGIO $163.06
- P/E Ratio
- KYN $13.79
- AGIO $3.00
- Revenue Growth
- KYN N/A
- AGIO 36.79
- 52 Week Low
- KYN $7.84
- AGIO $20.96
- 52 Week High
- KYN $9.88
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- KYN 38.67
- AGIO 28.75
- Support Level
- KYN $11.71
- AGIO $37.20
- Resistance Level
- KYN $13.36
- AGIO $44.46
- Average True Range (ATR)
- KYN 0.32
- AGIO 4.27
- MACD
- KYN -0.18
- AGIO -2.06
- Stochastic Oscillator
- KYN 23.08
- AGIO 1.06
About KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.